Hormone Receptor-Negative Breast Carcinoma

Hormone Receptor-Negative Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

8 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 6
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 17%
Top sponsor: Antonio Giordano, MD
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04602117	ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer	withdrawn	Phase 1	0	QuantumLeap Healthcare CollaborativeOTHER	1	Nov 18, 2023	clinicaltrials

Data updated 23 days agoSource updated Nov 18, 2023source: clinicaltrials